SCHEMBL6766698

SCHEMBL6766698

CNS(=O)(=O)c1ccc(Cl)c(Cl)c1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.45
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA3 P07451 1/20 0.45
CA4 P22748 1/20 0.45
CA6 P23280 1/20 0.45
CA5A P35218 1/20 0.45
CA7 P43166 1/20 0.45
CA9 Q16790 1/20 0.45
CA13 Q8N1Q1 1/20 0.45
CA14 Q9ULX7 1/20 0.45
CA5B Q9Y2D0 1/20 0.45
GSTO1 P78417 1/20 0.44
TSHR P16473 2/20 0.42
HTT P42858 2/20 0.42
VCAM1 P19320 1/20 0.42
NR3C1 P04150 1/20 0.41
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4030951 0.84 WDR5 (0.50) CA12CA1CA2CA3CA4
SCHEMBL2372746 0.82 PTGES2 (0.54) TSHRPTGES2CCR4MCOLN3
SCHEMBL9577112 0.79 CA1 (0.41) CA12CA1CA2CA3CA4
SCHEMBL9577092 0.79 NR3C1 (0.50) PKMGSTO1TSHRHTTNR3C1
SCHEMBL13545101 0.78 GSTO1 (0.44) CA12CA1CA2CA3CA4
SCHEMBL3527829 0.78 GSTO1 (0.44) CA12CA1CA2CA3CA4
SCHEMBL13684166 0.76 GSTO1 (0.43) CA12CA1CA2CA3CA4
SCHEMBL7972629 0.76 HTT (0.46) PKMTSHRHTTNR3C1LMNA
SCHEMBL16002831 0.75 MEN1 (0.56) TSHRLMNAPOLBMAPTALDH1A1
SCHEMBL13542992 0.75 GSTO1 (0.42) CA12CA1CA2CA3CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use LABORATORIES FOURNIER S.A. (FR) 2004-04-01 US disclosed
CN-1484633-A N (phenylsulphonyl) glycine derivatives and their therapentic use ʵ���Ҹ���Ү��˾ 2004-03-24 CN disclosed
EP-1351928-A2 NOVEL N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE LABORATOIRES FOURNIER S.A. (FR) 2003-10-15 EP disclosed
WO-2002053516-A2 N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE LABORATOIRES FOURNIER SA (FR) 2002-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use GLS, GLS2, GLRB PKM 1700/4885CA12 3089/4885CA1 2892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.